BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 21, 2023
Product Development

Vir’s first shot at ‘day one solution’ for influenza A misses Phase II endpoints

Prophylactic mAb was positioned as a bulwark against a potential flu pandemic
BioCentury | Jan 31, 2023
Distillery Therapeutics

A broadly acting neuraminidase-targeted mAb for influenza

BioCentury | Sep 6, 2022
Distillery Therapeutics

A single-dose inactivated whole-virus vaccine for influenza A

BioCentury | Dec 11, 2021
Product Development

Without clear differentiation, Moderna flu readout dents shares

First Phase I data for seasonal flu vaccine draw comparison to existing product, raise concerns about adverse events
BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

BioCentury’s roundup of translational news
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

Pneumagen targeting infections, cancer by co-opting and enhancing microbial carbohydrate binders
BioCentury | Dec 5, 2019
Company News

Deerfield propels Civetta with $53M series A

How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

How companies are broadening the reach of flu vaccines beyond seasonal strains
Items per page:
1 - 10 of 519